Skip to main content
. 2015 Sep 27;55(3):450–460. doi: 10.1093/rheumatology/kev354

Table 2.

Baseline clinical and serological characteristics of patients in included studies

Reference Age at diagnosis, mean (s.d.) or median (range) Sex, n Diagnostic criteria and testing Serological profile
Alamanos et al. [8] 55 (13)

  • M: 20

  • F: 420

  • American-European consensus criteria for pSS (2002)

  • Altered ocular test: 100%

  • Altered parotid scintigraphy: 87%

  • Salivary gland biopsy: 99%

  • RF: 32%

  • ANA: 94%

  • SSA/SSB: 51%/40%

  • Cryoglobulins: 28%
Brito-Zeron et al. [16] 57 (NR)

  • M: 19

  • F: 247

  • European study group criteria (1993)

  • American-European consensus criteria for pSS (2002)

 NR
Brito-Zeron et al. [5] 54 (15)

  • M: 63

  • F: 982

  • American-European consensus criteria for pSS (2002)

  • Dry mouth/dry eyes: 95%/95%

  • Altered ocular test: 92%

  • Altered parotid scintigraphy: 86%

  • Salivary gland biopsy: 88%

  • RF: 53%

  • ANA: 91%

  • SSA/SSB: 74%/46%

  • Cryoglobulins: 11%

  • Low C3/C4: 10%/12%
Horvath et al. [9]

  • M: 48 (12)

  • F: 50 (11)

  • M: 60

  • F: 487

  • Fox RI criteria (1986)

  • American-European consensus criteria for pSS (2002)

  • RF: 30%

  • ANA: 65%

  • SSA/SSB: 77%/55%

  • Cryoglobulins: 6%

  • Low C3/C4: 22%
Ioannidis et al. [17] 53 (IQR 44–68)

  • M:42

  • F: 681

  • European study group criteria (1993)

  • Dry mouth/dry eyes: 95%/96%

  • Altered ocular test: 87%

  • Salivary gland biopsy: 98%

  • RF: 52%

  • ANA: 81%

  • SSA/SSB: 48%/27%

  • Cryoglobulins: NR

  • Low C3/C4: 3%/20%
Nannini et al. [6] 59 (range 23–95)

  • M: 9

  • F: 96

  • American-European consensus criteria for pSS (2002)

  • Dry mouth/dry eyes: 95%/95%

  • Altered ocular test: 90%

  • Salivary gland biopsy: 50%

  • RF: 56%

  • ANA: 70%

  • SSA/SSB: 69%/55%

  • Cryoglobulins: NR

  • Low C3/C4: NR
Pertovaara et al. [18] 62 (at last follow-up)

  • M: NR

  • F: NR

  • Modified California criteria for pSS

  • Dry mouth/dry eyes: 88%/72%

  • Altered ocular test: 89%

  • RF: 46%

  • ANA: 67%

  • SSA/SSB: NR

  • Cryoglobulins: NR

  • Low C3/C4: NR
Theander et al. [19] 57 (range 11–84)

  • M: 43

  • F: 441

  • Copenhagen criteria, European criteria (1993) or the American-European consensus criteria for pSS (2002)

  • Salivary gland biopsy: 52%

  • RF: 34%

  • ANA: 74%

  • SSA/SSB: 31%

  • Cryoglobulins: NR

  • Low C3/C4: NR
Thomas et al. [7]

  • M: 55 (NR)

  • F: 60 (NR)

  • M: 133

  • F: 701

 ICD-9 diagnostic codes NR
Weng et al. [20]

  • M: 58 (15)

  • F: 53 (14)

  • M: 312

  • F: 3040

 ICD-9 diagnostic codes, based on American-European consensus criteria for pSS (2002) NR

F: female; ICD-9: International Classification of Diseases, 9th revision; IQR: interquartile range; M: male; NR: not reported; pSS: primary SS.